Diazepam binding inhibitor (DBI) in the plasma of pediatric and adult epileptic patients

Carlo Ferrarese, Tiziana Cogliati, Rachele Tortorella, Claudio Zucca, Graziella Bogliun, Ettore Beghi, Davide Passoni, Chiara Zoia, Barbara Begni, Larissa Airoldi, Hannu Alho, Lodovico Frattola

Research output: Contribution to journalArticlepeer-review


The polypeptide diazepam binding inhibitor (DBI) displays epileptogenic activity by binding to benzodiazepine receptors. We analyzed DBI concentrations in the plasma of pediatric and adult epileptic patients, as a possible peripheral marker in epilepsy. DBI plasma concentrations are significantly higher (+ 62%, P <0.001) in adult patients and slightly but significantly higher (+ 15%, P <0.01) in pediatric patients, compared to age-related controls. Strikingly, plasma DBI is much higher (+ 81%, P <0.001) in generalized epilepsy in adults and in drug-resistant pediatric and adult patients. Based on these findings, plasma DBI may be considered as a peripheral biological marker of epilepsy and, in association with lymphocyte benzodiazepine receptor density, of anticonvulsant drug responsiveness.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalEpilepsy Research
Issue number2
Publication statusPublished - Jan 1998


  • Diazepam binding inhibitor
  • Drug resistance
  • Epilepsy
  • Peripheral benzodiazepine receptors

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology


Dive into the research topics of 'Diazepam binding inhibitor (DBI) in the plasma of pediatric and adult epileptic patients'. Together they form a unique fingerprint.

Cite this